Cadrenal Therapeutics (NASDAQ:CVKD) CEO Quang Pham Sells 5,893 Shares of Stock

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) CEO Quang Pham sold 5,893 shares of the business’s stock in a transaction that occurred on Monday, June 8th. The shares were sold at an average price of $4.38, for a total value of $25,811.34. Following the completion of the sale, the chief executive officer owned 167,331 shares of the company’s stock, valued at $732,909.78. This trade represents a 3.40% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Cadrenal Therapeutics Price Performance

Cadrenal Therapeutics stock opened at $4.14 on Thursday. The stock has a market capitalization of $11.88 million, a PE ratio of -0.74 and a beta of 1.59. Cadrenal Therapeutics, Inc. has a 12 month low of $3.90 and a 12 month high of $15.99. The business has a 50 day simple moving average of $5.08 and a 200-day simple moving average of $6.73.

Cadrenal Therapeutics (NASDAQ:CVKD) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($1.04) EPS for the quarter, beating analysts’ consensus estimates of ($1.51) by $0.47. On average, equities research analysts anticipate that Cadrenal Therapeutics, Inc. will post -5.52 EPS for the current fiscal year.

Institutional Trading of Cadrenal Therapeutics

Several large investors have recently made changes to their positions in the company. DRW Securities LLC purchased a new stake in shares of Cadrenal Therapeutics during the fourth quarter worth approximately $171,000. Citadel Advisors LLC purchased a new stake in Cadrenal Therapeutics during the 3rd quarter valued at about $274,000. Geode Capital Management LLC grew its stake in Cadrenal Therapeutics by 14.3% during the 4th quarter. Geode Capital Management LLC now owns 14,528 shares of the company’s stock valued at $98,000 after acquiring an additional 1,818 shares in the last quarter. Finally, JPMorgan Chase & Co. purchased a new stake in Cadrenal Therapeutics during the 3rd quarter valued at about $103,000. 7.92% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts have recently commented on CVKD shares. HC Wainwright cut their target price on shares of Cadrenal Therapeutics from $32.00 to $13.00 and set a “buy” rating for the company in a research note on Tuesday, April 7th. Weiss Ratings reissued a “sell (e+)” rating on shares of Cadrenal Therapeutics in a research note on Monday, April 20th. Finally, Wall Street Zen raised shares of Cadrenal Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 9th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Cadrenal Therapeutics currently has an average rating of “Hold” and a consensus price target of $13.00.

About Cadrenal Therapeutics

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.